147 related articles for article (PubMed ID: 9363862)
21. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
Greenblatt MS; Mangalik A; Ferguson J; Elias L
Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
[TBL] [Abstract][Full Text] [Related]
22. Phase I and pharmacokinetic evaluation of all-trans-retinoic acid in pediatric patients with cancer.
Smith MA; Adamson PC; Balis FM; Feusner J; Aronson L; Murphy RF; Horowitz ME; Reaman G; Hammond GD; Fenton RM
J Clin Oncol; 1992 Nov; 10(11):1666-73. PubMed ID: 1403049
[TBL] [Abstract][Full Text] [Related]
23. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer.
Budd GT; Adamson PC; Gupta M; Homayoun P; Sandstrom SK; Murphy RF; McLain D; Tuason L; Peereboom D; Bukowski RM; Ganapathi R
Clin Cancer Res; 1998 Mar; 4(3):635-42. PubMed ID: 9533531
[TBL] [Abstract][Full Text] [Related]
24. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report.
Fouladi M; Park JR; Stewart CF; Gilbertson RJ; Schaiquevich P; Sun J; Reid JM; Ames MM; Speights R; Ingle AM; Zwiebel J; Blaney SM; Adamson PC
J Clin Oncol; 2010 Aug; 28(22):3623-9. PubMed ID: 20606092
[TBL] [Abstract][Full Text] [Related]
25. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
26. Phase I trial of all-trans retinoic acid in patients with treated head and neck squamous carcinoma.
Park SH; Gray WC; Hernandez I; Jacobs M; Ord RA; Sutharalingam M; Smith RG; Van Echo DA; Wu S; Conley BA
Clin Cancer Res; 2000 Mar; 6(3):847-54. PubMed ID: 10741706
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
[TBL] [Abstract][Full Text] [Related]
28. Phase I evaluation of all-trans-retinoic acid in adults with solid tumors.
Lee JS; Newman RA; Lippman SM; Huber MH; Minor T; Raber MN; Krakoff IH; Hong WK
J Clin Oncol; 1993 May; 11(5):959-66. PubMed ID: 8487058
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer.
Rizvi NA; Marshall JL; Ness E; Yoe J; Gill GM; Truglia JA; Loewen GR; Jaunakais D; Ulm EH; Hawkins MJ
Clin Cancer Res; 1998 Jun; 4(6):1437-42. PubMed ID: 9626460
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic study of all-trans-retinoyl-beta-D-glucuronide in Sprague-Dawley rats after single and multiple intravenous administration(s).
Lin HS; Barua AB; Olson JA; Low KS; Chan SY; Shoon ML; Ho PC
J Pharm Sci; 2001 Dec; 90(12):2023-31. PubMed ID: 11745761
[TBL] [Abstract][Full Text] [Related]
31. A phase I-II study of 9-cis retinoic acid and interferon-alpha2b in patients with advanced renal-cell carcinoma: an NCIC Clinical Trials Group study.
Miller WH; Reyno LM; Loewen GR; Huan S; Winquist E; Moore M; Cato A; Jaunakais D; Truglia JA; Matthews S; Dancey J; Eisenhauer E
Ann Oncol; 2000 Nov; 11(11):1387-9. PubMed ID: 11142476
[TBL] [Abstract][Full Text] [Related]
32. Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors.
Catimel G; Chabot GG; Guastalla JP; Dumortier A; Cote C; Engel C; Gouyette A; Mathieu-Boué A; Mahjoubi M; Clavel M
Ann Oncol; 1995 Feb; 6(2):133-40. PubMed ID: 7786821
[TBL] [Abstract][Full Text] [Related]
33. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and metabolism of all-trans- and 13-cis-retinoic acid in pulmonary emphysema patients.
Muindi JR; Roth MD; Wise RA; Connett JE; O'Connor GT; Ramsdell JW; Schluger NW; Romkes M; Branch RA; Sciurba FC;
J Clin Pharmacol; 2008 Jan; 48(1):96-107. PubMed ID: 18094222
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
36. A phase I trial of amifostine (WR-2721) and melphalan in children with refractory cancer.
Adamson PC; Balis FM; Belasco JE; Lange B; Berg SL; Blaney SM; Craig C; Poplack DG
Cancer Res; 1995 Sep; 55(18):4069-72. PubMed ID: 7664282
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial.
Sutton LM; Warmuth MA; Petros WP; Winer EP
Cancer Chemother Pharmacol; 1997; 40(4):335-41. PubMed ID: 9225952
[TBL] [Abstract][Full Text] [Related]
38. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
39. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
Schilsky RL; Hohneker J; Ratain MJ; Janisch L; Smetzer L; Lucas VS; Khor SP; Diasio R; Von Hoff DD; Burris HA
J Clin Oncol; 1998 Apr; 16(4):1450-7. PubMed ID: 9552051
[TBL] [Abstract][Full Text] [Related]
40. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
